Mast Cell and VEGF Profile in Canine Soft Tissue Tumors

PDF (English)
Опубликован: Ιουλ 9, 2023
Обновлен: 2023-07-09
Версии:
2023-07-09 (3)
DOI: https://doi.org/10.12681/jhvms.30129
V Ipek
Mehmet Akif Ersoy University, Faculty of Veterinary Medicine, Department of Pathology
O Kaplan
Mehmet Akif Ersoy University, Institute of Health Sciences
Аннотация

Canine soft tissue sarcomas are a complex group that is difficult to treat with high invasion and metastasis characteristics. These tumors are divided into a wide variety of subtypes, but due to their general mesenchymal characteristics and morphological similarities, they are under a single group called soft tissue tumors together with benign ones. Tumor microenvironment including mast cells promotes tumor angiogenesis, proliferation, invasion, and metastasis, as well as mediating the mechanism of therapeutic resistance. In this study, the presence and relationships of mast cells with VEGF in benign and malignant soft tissue tumors were evaluated. As a result, mast cells showed a significant increase in malignant tumors compared to benign ones. In the VEGF analyzes performed for interpreting of angiogenesis, the immunostaining scores were also higher in malignant tumors. To the authors' knowledge, there is no previous study investigating mast cells and angiogenesis in canine soft tissue tumors. This study revealed that mast cell and VEGF scores are higher in malignant tumors compared to benign ones and can be considered as a prognostic marker. However, any correlation between mast cells and VEGF immune expressions could not be detected.

Article Details
  • Раздел
  • Research Articles
Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 4.0 Всемирная.

Authors who publish with this journal agree to the following terms:

· Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

· Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

· Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Скачивания
Данные скачивания пока недоступны.
Библиографические ссылки
Abdel-Majid RM, Marshall JS (2004) Prostaglandin E2 Induces Degranulation-Independent Production of Vascular Endothelial Growth Factor by Human Mast Cells. J. Immunol. 172: 1227–1236.
Avallone G, Helmbold P, Caniatti M, Stefanello D, Nayak RC, Roccabianca P (2007) The spectrum of canine cutaneous perivascular wall
tumors: morphologic, phenotypic and clinical characterization. Vet.
Pathol. 44: 607–620.
Baneth V, Raica M, Cîmpean AM (2005) Assessment of angiogenesis in
soft-tissue tumors. Rom. J. Morphol. Embryol. 46: 323–327.
Bostock DE, Dye MT (1980) Prognosis after surgical excision of canine
fibrous connective tissue sarcomas. Vet. Pathol. 17: 581–588.
Caso G, Barry C, Patejunas G (2009) Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient Mice. J. Hematol. Oncol. 2: 7.
Chase D, Bray J, Ide A, Polton G (2009) Outcome following removal
of canine spindle cell tumours in first opinion practice: 104 cases. J.
Small Anim. Pract. 50: 568–574.
Dennis MM, McSporran KD, Bacon NJ, Schulman FY, Foster RA, Powers BE (2011) Prognostic Factors for Cutaneous and Subcutaneous
Soft Tissue Sarcomas in Dogs. Vet. Pathol. 48: 73–84.
Detmar M, Brown LF, Schön MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the
skin of VEGF transgenic mice. J. Invest. Dermatol. 111: 1–6.
Enzinger F, Weiss S (1988) Malignant fibrohistiocytic tumors. In: S Weiss
and F Enzinger, editor. Soft Tissue Tumors St. Louis, Missouri: Mosby. p. 269–300.
Fitzsimons C, Molinari B, Duran H, Palmieri M, Davio C, Cricco G, Bergoc R, Rivera E (1997) Atypical association of H1 and H2 histamine
receptors with signal transduction pathways during multistage mouse
skin carcinogenesis. Inflamm. Res. 1997 468 46: 292–298.
Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature
: 58–61.
Gaitero L, Añor S, Fondevila D, Pumarola M (2008) Canine Cutaneous
Spindle Cell Tumours with Features of Peripheral Nerve Sheath
Tumours: A Histopathological and Immunohistochemical Study. J.
Comp. Pathol. 139: 16–23.
Giorno R, Claman HN (1988) Mast cells and neurofibromatosis. Neurofibromatosis 1: 100–104.
Goldschmidt M, Hendrick M (2002) Tumors of the skin and soft tissues.
In: D Meuten, editor. Tumors in domestic animals Ames, Iowa: Iowa
State Univ Pr. p. 109–111.
Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ (2007) Mast
cell–derived interleukin 10 limits skin pathology in contact dermatitis
and chronic irradiation with ultraviolet B. Nat. Immunol. 2007 810
: 1095–1104.
Gross T, Ihrke P, Walder E, Affolter V (2005) Skin diseases of the dog and
cat: clinical and histopathologic diagnosis. Oxford: Blackwell.
Gruber B, Marchese M, Kiely J, Schwartz L, Schecter N (1988) 520 Human mast cell products degrade connective tissue matrix. J Allergy
Clin Immunol 81: 298.
Hendrick M, Mahaffeey E, Moore F, Vos J, Walder E (1998) Histological classification of mesenchymal tumors of skin and soft tissues of
domestic animals, Vol. 2. Washington DC: Armed Forces Institute of
Pathology.
Hinkle D, Wiersma W, Jurs S (2003) Applied Statistics for the Behavioral
Sciences. Boston: Houghton Mifflin.
Isaacson P (1976) Mast cells in benign nerve sheath tumours. J. Pathol.
: 193–196.
Johnson MD, Kamso-Pratt J, Federspiel CF, Whetsell WO (1989) Mast
cell and lymphoreticular infiltrates in neurofibromas. Comparison
with nerve sheath tumors. Arch. Pathol. Lab. Med. 113: 1263–1270.
Kamarlis RK, Lubis MN, Hernowo BS, Harapan H, Kar AS (2017) Immunoexpression of P63 and SOX2 in triple-negative breast cancers,
Indonesia. F1000Research 6: 1780.
Koestner A, Higgins R (2002) Tumors of the nervous system. In: D Meuten, editor. Tumors in domestic animals Ames: Iowa State Press. p.
–738.
Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC, Withrow SJ
(1997) Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J. Am. Vet. Med. Assoc. 211:
–1151.
Mayer MN, LaRue SM (2005) Soft tissue sarcomas in dogs. Can. Vet. J.
: 1048.
Metcalfe DD, Baram D, Mekori YA (1997) Mast cells. Physiol. Rev. 77:
–1079.
Möller A, Henz BM, Grützkau A, Lippert U, Aragane Y, Schwarz T,
Krüger-Krasagakes S (1998) Comparative cytokine gene expression: regulation and release by human mast cells. Immunology 93:
–295.
Mulaka M (2012) A guide to appropriate use of correlation coefficient in
medical research. Malawi Med. J. 24: 69–71.
Olsson Y (1968) Mast Cells in the Nervous System. Int. Rev. Cytol. 24:
–70.
Parwaresch MR, Homy HP, Lennert K (1985) Tissue mast cells in health
and disease. Pathol. - Res. Pract. 179: 439–461.
Rak JW, St. Croix BD, Kerbel RS (1995) Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer.
Drugs 6: 3–18.
Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A (2004) Mast cell
contribution to angiogenesis related to tumour progression. Clin. Exp.
Allergy 34: 1660–1664.
Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P (2003)
Tumor vascularity and tryptase-positive mast cells correlate with a
poor prognosis in melanoma. Eur. J. Clin. Invest. 33: 420–425.
Savas O, Ipek V (2021) Investigation of Calprotectin Positive Leukocytes
in Canine Soft Tissue Tumors. J. Res. Vet. Med. 40: 77–87.
Sener S, Ipek V (2021) Investigation of brain mast cells in ovine encephalitic listeriosis. Biotech. Histochem. .
Starkey JR, Crowle PK, Taubenberger S (1988) Mast-cell-deficient W/
Wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. cancer
: 48–52.
Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C, Xue FX
(2016) Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J. Hematol. Oncol. 9: .
Theoharides TC, Conti P (2004) Mast cells: the Jekyll and Hyde of tumor
growth. Trends Immunol. 25: 235–241.
Thrall D, EL G (1995) Soft-tissue sarcomas. Semin Vet Med Surg (Small
Anim) 10: 173–179.
Tth T, Tth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N (2000) Cutaneous malignant melanoma: Correlation between neovascularization
and peritumor accumulation of mast cells overexpressing vascular
endothelial growth factor. Hum. Pathol. 31: 955–960.
Tu Z, Xiao R, Xiong J, Tembo KM, Deng X, Xiong M, Liu P, Wang M,
Zhang Q (2016) CCR9 in cancer: Oncogenic role and therapeutic targeting. J. Hematol. Oncol. 9: .
Ueda T, Aozasa K, Tsujimoto M, Yoshikawa H, Kato T, Ono Ke, Matsumoto Ke (1988) Prognostic Significance of Mast Cells in Soft Tissue
Sarcoma. Cancer 62: 2419.
Ullrich SE, Nghiem DX, Khaskina P (2007) Suppression of an Established Immune Response by UVA: A Critical Role for Mast Cells.
Photochem. Photobiol. 83: 1095.
Vasconcelos RAT de, Guimarães Coscarelli P, Vieira TM, Noguera WS,
Rapozo DCM, Acioly MA (2019) Prognostic significance of mast
cell and microvascular densities in malignant peripheral nerve sheath
tumor with and without neurofibromatosis type 1. Cancer Med. 8:
–981.
Weiss S, Goldblum J (2001) Perivascular tumors. In: S Weiss and J Goldblum, editor. Soft tissue tumors St. Louis MO: Mosby. p. 985–1035.